ArticleBMC medicine2026

Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma.

Jie Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.